https://portal.oup.vc/news/default.asp Sun, 19 Apr 2026 19:16:28 GMT Thu, 17 Oct 2019 20:49:06 GMT Copyright © 2019 Osage University Partners https://portal.oup.vc/news/news.asp?id=475200 https://portal.oup.vc/news/news.asp?id=475200 ArsenalBio launched with an $80M Seed financing syndicated by Westlake Village BioPartners, Kleiner Perkins, PICI, and the UCSF Foundation with participation from OUP. Founded in 2018, Arsenal is developing cellular drug discovery tools intended to provide medicines for cancer treatment. The company was founded based on work by Alex Marson of UC San Francisco, E. John Wherry of University of Pennsylvania, Nick Haining of Dana-Farber, and Brad Bernstein of Harvard University.

Arsenal’s novel approach can directly edit the genome of a patient’s impaired immune system cells in vitro with an automatable process that increases the breadth, accuracy, and complexity of value-added genome edits (e.g., added potency, resistance to tumor evasion, increased tumor killing, reduction in toxicity) while dramatically reducing the current standards for COGS and CAPEX, and potentially the reverse logistics of central manufacturing.  Arsenal’s core technology is a proprietary non-viral DNA delivery process, exclusively licensed from UCSF, exhibiting a capacity to deliver rising amounts of DNA into human cells at declining cost per kilobase. Arsenal has also licensed IP from Dana-Farber Cancer Institute and University of Pennsylvania. More here. ]]> Thu, 17 Oct 2019 21:49:06 GMT https://portal.oup.vc/news/news.asp?id=475202 https://portal.oup.vc/news/news.asp?id=475202 OUP participated in the $60M Series B financing of Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune diseases. The round was co-led by Perceptive Advisors and RTW Investment, with participation from PBM Capital and OUP. 

Landos’ lead clinical asset, BT-11, is a first-in-class, oral therapeutic that acts locally in the gastrointestinal tract for treatment of inflammatory bowel disease (IBD). The company has completed Phase 1 clinical testing and has initiated Phase 2 clinical testing of BT-11 for inflammatory bowel disease in 2019. Landos also has a robust pipeline of new compounds for other autoimmune diseases, several of which Landos anticipates will advance to IND and Phase 1 clinical testing in 2020. The proceeds of the financing will be used towards Phase 2 trials for ulcerative colitis and Crohn's Disease. Read more here.]]> Tue, 13 Aug 2019 21:57:14 GMT